Pancreatic Cancer
If it’s your first time on this website, please read the disclaimer section.
Sep 28 – Oct 05, 2026
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This randomized phase 2b trial evaluated intravenous VCN-01 (oncolytic adenovirus) plus gemcitabine and nab-paclitaxel (GnP) versus GnP alone as first-line therapy for metastatic pancreatic ductal adenocarcinoma. In the full analysis set, VCN-01+GnP significantly improved median progression-free survival (7.0 vs 4.6 months, HR=0.55, P=0.011) and duration of response (11.2 vs 5.4 months, HR=0.22, P=0.004). Median overall survival was 10.8 vs 8.6 months (HR=0.57, P=0.055), with 18-month survival rates of 31.1% vs 8.5%. These findings suggest a potential new first-line treatment option for a challenging cancer, warranting further investigation in a phase 3 trial.
10.1038/s41591-026-04705-y
Sep 14 – Sep 21, 2026
Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This international, multicenter study developed and validated PANXEON, a blood-based assay combining a 10-miRNA signature with CA 19-9 for early-stage pancreatic ductal adenocarcinoma (PDAC) detection in 1,785 individuals. The miRNA signature achieved an 88.6% AUC and 83.8% sensitivity for early-stage PDAC, while the composite PANXEON score reached 86.8% sensitivity for stage I-II disease. Biomarker levels correlated with clinical status, decreasing after surgery or chemotherapy and increasing prior to disease recurrence, while also identifying 64.3% of high-grade dysplasia in high-risk cysts. This liquid biopsy approach offers a promising non-invasive tool for early cancer detection and longitudinal monitoring, warranting further large-scale prospective validation in clinical practice.
10.1038/s41591-026-04625-x
Aug 10 – Aug 17, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study investigated mechanisms of acquired resistance to daraxonrasib, a RAS(ON) multi-selective inhibitor, using ctDNA sequencing from 44 patients with metastatic pancreatic adenocarcinoma and preclinical models. Genomic alterations in the RAS signaling pathway emerged in 59% of patients, primarily through mutant KRAS amplifications (36%), alongside RTK (9%), MAPK (25%), and PI3K (9%) pathway changes. Notably, no secondary KRAS mutations were observed, suggesting that resistance is driven by pathway reactivation rather than target site modification. These findings support rational combination strategies using daraxonrasib with DNA damage response or RTK inhibitors to avert resistance and improve outcomes in pancreatic cancer patients.
10.1038/s41591-026-04537-w
Aug 03 – Aug 10, 2026
Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study analyzed the molecular landscape of 317 resected pancreatic ductal adenocarcinoma (PDAC) tumors from the PRODIGE-24/CCTG PA6 trial via DNA sequencing and transcriptomic subtyping to assess genomic alterations’ impact on adjuvant chemotherapy efficacy. In the mFOLFIRINOX (mFFX) group, classical tumors showed superior disease-free survival (DFS) versus basal-like tumors (sHR, 0.48 [95% CI, 0.31 to 0.77]). For KRAS-mutated patients, mFFX significantly improved DFS over gemcitabine (sHR, 0.60 [95% CI, 0.45 to 0.79]; p < .001), a benefit absent in KRAS wild-type tumors (interaction test, p = 0.010). While mFFX remains the standard adjuvant regimen for PDAC, these findings offer crucial insights into personalized cancer treatment, suggesting further investigation for KRAS wild-type tumors.
10.1200/JCO-25-02508
Jul 27 – Aug 03, 2026
Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study developed and validated PANCprAId, a deep learning biomarker using histology images to predict the relative benefit of adjuvant gemcitabine versus mFOLFIRINOX in 544 patients with resected pancreatic ductal adenocarcinoma. In the external validation cohort, the biomarker successfully stratified outcomes for both gemcitabine (HR 1.69) and mFOLFIRINOX (HR 2.02), showing significant treatment interaction for disease-free survival (p=0.003). These findings demonstrate that AI-driven analysis of standard whole-slide images can identify patients more likely to benefit from specific chemotherapy regimens based on distinct epithelial and stromal features. This tool offers a practical, histology-based approach to personalizing adjuvant treatment strategies in pancreatic cancer, potentially improving survival outcomes through precision oncology.
10.1200/JCO-26-00327